González LD, Arguedas OMJ, Rockbrand CLP

Language: Spanish
References: 12
Page: 56-63
PDF size: 491.91 Kb.

ABSTRACT

Pheochromocytoma is a neuroendocrine tumor derived from the neural crest, that is characteristic for producing catecholamines. Most of them present between the fourth and fifth decade, without preference for either gender. Around 20-40% of patients present with the classic triad, consisting of: intermittent headaches, tachycardia or palpitations, and diaphoresis. The diagnosis is mainly biochemical, through the quantification of metanephrines in blood and urine, which are consistently released therefore becoming a very sensitive marker, with low rate of false negatives. Pheochromocytoma has mainly a surgical management. Previous to the surgery, all patients despite having normal blood pressures, must be medicated with antihypertensives. Those tumors that are smaller than 15 cm should be resected through laparoscopic adrenalectomy. There are three major complications in the immediate postoperative of these tumors, which are: arterial hypertension, arterial hypotension and hypoglycemia. Its is a rare cause of hypertension in pregnant women, and around 10% of these tumors are present the pediatric population.

REFERENCES

1. Lam A. Update on paragangliomas and pheochromocytomas. Turkish Journal of Pathology. 2015; 31:105-112.

2. Oleaga A, Goñi F. Feocromocitoma: actualización diagnóstica y terapéutica. Endocrinología y Nutrición. 2008;55(5):202-216.

3. Subramaniam R. Pheochromocytoma – Current concepts in diagnosis and management. Trends in Anaesthesia and Critical Care. 2011;1(2):104-110.

4. Gupta P, Khurana M, Khadgawat R, Bal C, Kumar G, Sharma S, Tandon N et al. Plasma free metanephrine, normetanephrine, and 3-methoxytyramine for the diagnosis of pheochromocytoma/paraganglioma. Indian Journal of Endocrinology and Metabolism. 2015;19(5):633.

5. Bennett B, Johnson D, Panakos A, Rozenberg A. Unsuspected pheochromocytoma incidentally found on chest CT. Radiology Case Reports. 2018;13(1):191- 196.

6. Naranjo J, Dodd S, Martin Y. Perioperative Management of Pheochromocytoma. Journal of Cardiothoracic and Vascular Anesthesia. 2017;31(4):1427-1439.

7. Yu R, Nissen N, Chopra P, Dhall D, Phillips E, Wei M. Diagnosis and Treatment of Pheochromocytoma in an Academic Hospital from 1997 to 2007. The American Journal of Medicine. 2009;122(1):85-95

8. Cano Megías M, Rodríguez Puyol D, Fernández Rodríguez L, Sención Martinez G, Martínez Miguel P. Feocromocitoma-paraganglioma: del diagnóstico bioquímico al genético. Nefrología. 2016;36(5):481- 488.

9. Fishbein L, Nathanson K. Pheochromocytoma and Paraganglioma Susceptibility Genes. JAMA Oncology. 2017;3(9):1212.

10. Martins R, Bugalho M. Paragangliomas/ Pheochromocytomas: Clinically Oriented Genetic Testing. International Journal of Endocrinology. 2014; 2014:1-14.

11. Rasquin L, Prater J, Mayrin J, Minimo C. Simultaneous Pheochromocytoma, Paraganglioma, and Papillary Thyroid Carcinoma without Known Mutation. Case Reports in Endocrinology. 2018; 2018:1-3.

12. Sarathi V. Characteristics of pediatric pheochromocytoma/paraganglioma. Indian Journal of Endocrinology and Metabolism. 2017;21(3):470.